Histone methyltransferase PRDM9 promotes survival of drug-tolerant persister cells in glioblastoma [RNA-seq]
RNA-seq (gene expression) · human · 12 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 12 samples: 3 × Parent_n= vs 3 × MRK-740_n= vs 3 × CMPD1_n= vs 2 × CMPD1+MRK-740_n=Groups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Histone methyltransferase PRDM9 promotes survival of drug-tolerant persister cells in glioblastomaNature communications · 2025
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE262251_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1090907 and SRA study SRP497321. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 11 samples.
How we read this: 4 replicated groups read from 12 sample titles; they account for 11 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8161065 Parent_n=1 Parent_n=
- GSM8161066 Parent_n=2 Parent_n=
- GSM8161067 Parent_n=3 Parent_n=
- GSM8161068 MRK-740_n=1 MRK-740_n=
- GSM8161069 MRK-740_n=2 MRK-740_n=
- GSM8161070 MRK-740_n=3 MRK-740_n=
- GSM8161071 CMPD1_n=1 CMPD1_n=
- GSM8161072 CMPD1_n=2 CMPD1_n=
- GSM8161073 CMPD1_n=3 CMPD1_n=
- GSM8161074 CMPD1+MRK-740_n=1 CMPD1+MRK-740_n=
- GSM8161075 CMPD1+MRK-740_n=2 CMPD1+MRK-740_n=
- GSM8161076 CMPD1+MRK-740-n=3
- GSE279413 Histone methyltransferase PRDM9 promotes survival of drug-tolerant persister cells in glioblastoma [ChIP-seq] 16 samples shares prdm9, methyltransferase, drug-tolerant, glioblastoma, persister, promotes, survival, histone
- GSE296115 The Histone Methyltransferase KMT2D is a Critical Mediator of Lineage Plasticity and Therapeutic Response in Castration Resistant Prostate Cancer [LNCaP Bulk RNA-Seq] 16 samples shares methyltransferase, histone
- GSE303201 Identification of a shared drug-tolerant persister program in triple-negactive breast cancer across treatments and patients [scRNA-Seq] 10 samples shares drug-tolerant, persister
- GSE296270 The Histone Methyltransferase KMT2D is a Critical Mediator of Lineage Plasticity and Therapeutic Response in Castration Resistant Prostate Cancer 118 samples shares methyltransferase, histone
- GSE280454 Identification of a shared drug-tolerant persister program in triple-negative breast cancer across treatments and patients [CUT&Tag] 23 samples shares drug-tolerant, persister
- GSE217130 The methyltransferases METTL7A and METTL7B confer resistance of cancer cells to thiol-based histone deacetylate inhibitors 22 samples shares methyltransferase, histone
- GSE286432 An EGFR Co-amplified Long Noncoding RNA HELDR Promotes Glioblastoma Malignancy through KAT7-driven gene programs [ChIRP] 21 samples shares glioblastoma, promotes
- GSE260499 Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in NSCLC (scRNA-Seq) 20 samples shares drug-tolerant, persister
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.